[A20-105] Acalabrutinib (chronic lymphocytic leukaemia; pretreated) - Benefit assessment according to §35a Social Code Book V
Last updated 05.08.2021
Project no.:
A20-105
Commission:
Commission awarded on 30.11.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with previously treated chronic lymphocytic leukaemia (CLL)
Patients after pretreatment who have no 17p deletion or TP53 mutation and for whom chemo-immunotherapy is indicated: added benefit not proven.
Patients after pretreatment who have 17p deletion or TP53 mutation or for whom chemo-immunotherapy is not indicated for other reasons: added benefit not proven.
Patients after at least 2 pretreatments: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-103 | Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-104 | Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-54 | Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105 | Commission completed |
| G21-13 | Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-105 | Commission completed |
| A21-87 | Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105 | Commission completed |
Federal Joint Committee (G-BA)
2021-08-05: A G-BA decision was published.